| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,242,049 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
| Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
11 |
21 |
41 |
87 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Robert I |
President & CEO |
• • – |
2009-03-26 |
4 |
AS |
$2.00 |
$40,000 |
D/D |
(20,000) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-03-26 |
4 |
OE |
$1.20 |
$24,000 |
D/D |
20,000 |
42,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-03-17 |
4 |
AS |
$2.00 |
$9,076 |
D/D |
(4,538) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-03-17 |
4 |
OE |
$0.58 |
$2,632 |
D/D |
4,538 |
26,998 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-03-16 |
4 |
AS |
$2.00 |
$1,924 |
D/D |
(962) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-03-16 |
4 |
OE |
$0.58 |
$558 |
D/D |
962 |
23,422 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-03-02 |
4 |
AS |
$1.52 |
$7,716 |
D/D |
(5,000) |
59,500 |
|
- |
|
| Henderson John T |
Director |
– • – |
2009-02-19 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
500 |
|
- |
|
| Henderson John T |
Director |
– • – |
2009-02-19 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-02-02 |
4 |
AS |
$2.07 |
$10,753 |
D/D |
(5,000) |
64,500 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-01-02 |
4 |
AS |
$2.71 |
$14,188 |
D/D |
(5,000) |
69,500 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2008-12-01 |
4 |
AS |
$2.08 |
$10,765 |
D/D |
(5,000) |
74,500 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2008-11-03 |
4 |
AS |
$2.83 |
$14,600 |
D/D |
(5,000) |
79,500 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2008-09-26 |
4 |
S |
$4.65 |
$97,514 |
I/I |
(20,000) |
149,550 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2008-09-24 |
4 |
S |
$4.48 |
$96,804 |
I/I |
(20,000) |
169,550 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-09-15 |
4 |
AS |
$5.00 |
$29,190 |
D/D |
(5,838) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-09-15 |
4 |
OE |
$1.20 |
$7,006 |
D/D |
5,838 |
28,298 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-08-29 |
4 |
AS |
$5.20 |
$51,184 |
D/D |
(9,676) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-08-29 |
4 |
OE |
$1.20 |
$11,611 |
D/D |
9,676 |
32,136 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-08-15 |
4 |
AS |
$5.00 |
$26,500 |
D/D |
(5,300) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-08-15 |
4 |
OE |
$1.20 |
$4,667 |
D/D |
3,889 |
27,760 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-07-31 |
4 |
AS |
$5.00 |
$103,255 |
D/D |
(20,651) |
23,871 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2008-07-31 |
4 |
OE |
$2.00 |
$26,604 |
D/D |
13,302 |
44,522 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2008-07-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,000 |
189,550 |
|
- |
|
| Spudich James A |
Director |
– • – |
2008-04-25 |
4 |
AS |
$3.31 |
$6,632 |
D/D |
(2,000) |
180,600 |
|
- |
|
1115 Records found
|
|
Page 35 of 45 |
|
|
0.38 (0.71%) 
